Abbott, GSK to Develop PCR-Based Molecular Dx to Select Patients for Trial Skin Cancer Therapy | GenomeWeb

Abbott said today that it has signed a pact with GlaxoSmithKline to develop a PCR-based molecular diagnostic test for a specific biomarker to aid in selecting patients who may benefit from an immunotherapy under development at GSK.

The agreement builds on a partnership between the companies announced last year to develop a PCR test for the same protein biomarker — MAGE-A3 — to screen for non-small-cell lung cancer patients eligible to receive GSK's developmental NSCLC therapy, called MAGE-A3 Antigen-Specific Cancer Immunotherapeutic, or MAGE-A3 ASCI.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.